DXCM$76.88

DexCom shows strong multi-year growth, with revenue rising from $2.4B in FY2021 to $4.7B in FY2025 and TTM accelerating further to $4.8B. Net income has expanded even faster, though FY2021 was depressed and later years benefited from scale and leverage. Gross margin has drifted down from the high-60s to about 60%–61%, but operating margin improved materially to 19.6% in FY2025 and 21.5% TTM, showing healthy conversion of sales growth into earnings. The large positive other income in FY2023–FY2025 materially boosted pretax results, so underlying operating strength is somewhat better than reported net income suggests. Assuming this is a medical device/diabetes technology company, margins and growth look strong versus peers, though cost discipline and gross margin pressure remain key watchpoints.

DexCom’s balance sheet appears solid with good liquidity and improving capital strength. Total current assets were $4.0 billion in FY2025 against $2.1 billion of current liabilities, leaving comfortable working capital, while TTM current assets of $4.3 billion still exceed current liabilities of $2.2 billion. Cash and short-term investments declined to $2.0 billion in FY2025 from $2.6 billion in FY2024, but TTM recovered to $2.4 billion. Solvency improved meaningfully as total debt fell to $1.34 billion from $2.53 billion, and net cash turned positive to $662.8 million in FY2025 and $1.08 billion TTM. Shareholders’ equity rose to $2.75 billion, with retained earnings increasing steadily, though receivables and inventory are trending higher.

DexCom shows strong and improving cash generation, with operating cash flow rising from $442.5 million in FY2021 to $1.44 billion in FY2025, and TTM at $1.78 billion. Free cash flow also strengthened materially, from $53.3 million to $1.08 billion, with TTM at $1.43 billion and a 29.7% margin, indicating solid cash conversion after CapEx. Capital spending has stayed elevated at roughly $350 million per year, which looks consistent with ongoing growth investment rather than strain. Working capital movements are meaningful, especially receivables and inventory, but they have not prevented healthy cash generation. Share repurchases have been substantial, while debt usage appears limited aside from the 2023 issuance and later repayment, suggesting generally disciplined capital allocation.

DexCom shows a generally strong operating profile with a few areas to monitor. Liquidity remains comfortable: the current ratio and quick ratio recovered from the 2024 dip and are now around 1.95 and 1.58, suggesting solid short-term coverage. Leverage has improved meaningfully, with debt-to-equity falling from earlier elevated levels to 0.44 and debt-to-EBITDA near 1.0, indicating a more manageable balance sheet. Efficiency is also trending better, as asset turnover has climbed steadily and inventory turnover has been broadly stable. Profitability is a clear strength, with ROE, ROA, ROIC, and ROCE all improving over time and currently at strong levels, supporting a healthier return profile overall.

Historical data runs through FY2024, while the analyst-covered outlook begins in FY2025 and extends to FY2027, with forecast revenue and EPS both pointing higher than the recent historical base. Revenue growth was strong in FY2021-FY2023, slowed materially in FY2024, then reaccelerates to mid-teens in FY2025 before settling into low-double-digit growth, suggesting a steadier expansion path rather than a sharp surge. EPS is only available from FY2025, but projected EPS growth outpaces revenue growth in FY2025-FY2026, which implies improving margins. Forward P/E data for FY2026-FY2027 declines from 29.64 to 24.96 as growth persists, which looks broadly aligned. Analyst sentiment is firmly positive: 27 analysts, Strong Buy consensus, and a stable-to-slightly firmer recommendation mix with no recent sell ratings.